Minimising steroids in lupus nephritis--will B cell depletion pave the way? - Wikidata - wikimedia - TriplyDB

Minimising steroids in lupus nephritis--will B cell depletion pave the way?

Minimising steroids in lupus nephritis--will B cell depletion pave the way?

http://www.wikidata.org/entity/Q38095864

about

Organ damage in high-risk patients with systemic and incomplete lupus syndromes Adverse events and infectious burden, microbes and temporal outline from immunosuppressive therapy in antineutrophil cytoplasmic antibody-associated vasculitis with native renal function The history of pulse therapy in lupus nephritis (1976-2016).Profile of epratuzumab and its potential in the treatment of systemic lupus erythematosus.Insights into the epidemiology and management of lupus nephritis from the US rheumatologist's perspective.Systemic lupus erythematosus diagnosis and management.The glucocorticoid receptor 1A3 promoter correlates with high sensitivity to glucocorticoid-induced apoptosis in human lymphocytes.Efficacy and safety of anti-CD20 antibody rituximab for patients with refractory systemic lupus erythematosus.Successful treatment of refractory systemic lupus erythematosus using proteasome inhibitor bortezomib followed by belimumab: description of two cases.Targeting the B-cell pathway in lupus nephritis: current evidence and future perspectives.

P2860

Q35600608-5E82EDD5-2B98-4C65-9D78-E6BC4B8C1DF2 Q36134791-9003A3E3-2105-40F2-84B3-BE4367B699F6 Q36811760-8A5576A5-3373-422E-8B1A-660259000AAD Q38271939-BA32DE7B-B1ED-42C8-8504-74FE28E2976E Q38877052-0B045EA0-A6EC-4646-84B2-E97C6DD44469 Q39053129-F5154675-9956-49C7-9EE9-FDF2467A6B14 Q46468863-55D8EDEB-1E41-4F57-A3A3-4818BA9FEF0F Q50116281-66DC0BD8-49B5-4EC6-B2C9-53EF8BF37EAD Q51152275-42DD828F-2F37-44D5-A803-2B9847D8BA90 Q51345238-002F4ADC-FA99-45AD-9454-1FF03AA22D90

P2860

Minimising steroids in lupus nephritis--will B cell depletion pave the way?

http://www.wikidata.org/entity/Q38095864

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Minimising steroids in lupus nephritis--will B cell depletion pave the way?

@en

type

label

Minimising steroids in lupus nephritis--will B cell depletion pave the way?

@en

prefLabel

Minimising steroids in lupus nephritis--will B cell depletion pave the way?

@en

P1433

Q38095864-7B3AB0D0-FF83-4A58-A4EC-7B0664852964

P1476

Q38095864-A341848F-800D-4EE8-9062-88A0F19A2C1D

P2093

Q38095864-71C365E6-89BA-4B87-871E-BD4090301A47

P2860

Q38095864-046324C9-927E-4594-B833-9F385699551C

Q38095864-0994BEC3-EAAB-470A-B1B5-96640312890D

Q38095864-0FCD3F79-8412-4826-B675-30FC485EACD6

Q38095864-182A5A56-EFC4-4F31-A75B-4E73FD122230

Q38095864-191562E4-60A0-4D57-AD8A-8E27367B3E4D

Q38095864-22B4E1F6-EB1A-47C3-9AA4-E53558361196

Q38095864-277D8EBA-41C9-478F-962E-C4A995EC3A8D

Q38095864-3AB77486-8D30-409E-BAD3-F51121028184

Q38095864-3B1DCE9C-CAE8-4831-A3A4-7245BA03039E

Q38095864-3E4CA768-E357-4C00-8B01-E96E62CF0054

P304

Q38095864-B19C5C20-8B6F-4735-9A48-9C623177C557

P31

Q38095864-056DCBFD-9EA5-4F85-AA51-A614E0B29F4D

P356

Q38095864-35986780-7B80-4AE3-87DD-57B1F98F104D

P433

Q38095864-8611B942-B45E-481D-8CCC-36AF48A77583

P478

Q38095864-816F6671-C651-4D43-BA74-050D4C10B241

P50

Q38095864-A97BFF3D-045F-4CCB-9C1A-6AFEB91EDA2B

P577

Q38095864-1573C6E4-ECEC-440F-95D2-AB3A74597EAE

P698

Q38095864-296A7D5E-DBA4-4A72-BBF7-6D70AA877263

P356

0961203313476155

P1433

P1476

Minimising steroids in lupus nephritis--will B cell depletion pave the way?

@en

P2093

L Lightstone

http://www.w3.org/2001/XMLSchema#string

P2860

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases.

The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide.

Detection of coronary artery disease and the role of traditional risk factors in the Hopkins Lupus Cohort.

Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: pooled data from European cohorts.

Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis

Trends in the incidence, demographics, and outcomes of end-stage renal disease due to lupus nephritis in the US from 1995 to 2006.

Therapy of lupus nephritis: lessons learned from clinical research and daily care of patients.

Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response.

P304

390-399

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/0961203313476155

http://www.w3.org/2001/XMLSchema#string

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

22

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23553782

http://www.w3.org/2001/XMLSchema#string